Skye Herbals Forum
May 13, 2008, 08:06:22 AM *
Welcome, Guest. Please login or register.
Did you miss your activation email?

Login with username, password and session length
News: Let us know what you think of the new changes here on the site.  Also, feel free to post comments and questions.
 
   Home   Help Search Login Register  
Pages: [1]
  Print  
Author Topic: Milk thistle and indinavir  (Read 3820 times)
Admin
Administrator
Sr. Member
*****
Posts: 212


WWW
« on: March 20, 2005, 07:58:31 AM »

A randomized controlled pharmacokinetics study and meta-analysis.

Mills E, Wilson K, Clarke M, Foster B, Walker S, Rachlis B, Degroot N, Montori VM, Gold W, Phillips E, Myers S, Gallicano K.

Faculty of Health Sciences, Clinical Epidemiology and Biostatistics, McMaster University, HSC-2C12, 1200 Main Street West, Hamilton, ON, L8N 3Z5, Canada, millsej@mcmaster.ca.

OBJECTIVES: To determine whether ingestion of milk thistle affects the pharmacokinetics of indinavir. METHODS: We conducted a three-period, randomized controlled trial with 16 healthy participants. We randomized participants to milk thistle or control. All participants received initial dosing of indinavir, and baseline indinavir levels were obtained (AUC(0-8)) (phase I). The active group were then given 450 mg milk-thistle extract capsules to be taken t.i.d. from day 2 to day 30. The control group received no plant extract. On day 29 and day 30, indinavir dosing and sampling was repeated in both groups as before (phase II). After a wash-out period of 7 days, indinavir dosing and sampling were repeated as before (phase III). RESULTS: All participants completed the trial, but two were excluded from analysis due to protocol violation. There were no significant between-group differences. Active group mean AUC(0-8) indinavir decreased by 4.4% (90% CI, -27.5% to -26%, P=0.78) from phase I to phase II in the active group, and by 17.3% (90% CI, -37.3% to +9%, P=0.25) in phase III. Control group mean AUC(0-8) decreased by 21.5% (90% CI, -43% to +8%, P=0.2) from phase I to phase II and by 38.5% (90% CI, -55.3% to -15.3%, P=0.01) of baseline at phase III. To place our findings in context, milk thistle-indinavir trials were identified through systematic searches of the literature. A meta-analysis of three milk thistle-indinavir trials revealed a non-significant pooled mean difference of 1% in AUC(0-8) (95% CI, -53% to 55%, P=0.97). CONCLUSIONS: Indinavir levels were not reduced significantly in the presence of milk thistle.

PMID: 15666173 [PubMed - as supplied by publisher]
Logged

Pages: [1]
  Print  
 
Jump to:  

Powered by MySQL Powered by PHP Powered by SMF 1.1.3 | SMF © 2006-2007, Simple Machines LLC Valid XHTML 1.0! Valid CSS!